SUPT7L

Across TCGA pan-cancer cohorts, SUPT7L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SUPT7L data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SUPT7L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SUPT7L expression acts as an unfavorable survival marker.

SKCM, PCPG, and SCLC are the cancer types where SUPT7L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	0.230	0.736	<.001	12	view →
PCPG	DFS	Median	All	0.094	0.768	.008	6	view →
SCLC	OS	Median	All	0.055	0.653	<.001	6	view →
BLCA	DFS	Median	IV	0.173	0.473	.018	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SUPT7L–SKCM (OS)

Open the SKCM breakdown →